Bharat Biotech
The Indian Council of Medical Research (ICMR) has worked closely with Bharat Biotech International Limited (BBIL) on the possible new coronavirus vaccine.
The indigenous vaccine Covaxin could now be launched to the public by 15 August by Bharat Biotech and ICMR.
By 15 August, after clinical trials have been completed, ICMR expects to launch the Covid vaccine. In order to intensify these efforts, ICMR has sent the highest priority to all shareholders.
ICMR developed BBIL-partnered indigenous vaccine Covid-19 (BBV152 COVID). On Thursday, an official stated that the ICMR has selected 12 institutes for clinical trials for the country’s first indigenous vaccine.
The 12 institutes have been requested by the ICMR to fast track the clinical trials of the vaccine as it remains the government’s highest priority projects.
However, the final result will depend on cooperation among all the clinical trial sites involved in this project, the ICMR said to selected institutions.
In collaboration with the ICMR and the National Institute of Virology (NIV), Hyderabad-based Bharat Biotech successfully developed Covaxin. In NIV, Pune, the Sara-coV-2 strain was isolated and delivered to BBIL.
